Cited by 183Hormonal and reproductive studiesProstate Cancer Treatment and ResearchProstate Cancer Diagnosis and Treatment

The DOI matches its Crossref record; 32 of the 33 references it cites were found in a registry or an index.

Testosterone Replacement Therapy in Patients with Prostate Cancer After Radical Prostatectomy

Open access

Pastuszak, Alexander W., Pearlman, Amy M., Lai, Win Shun, Godoy, Guilherme, Sathyamoorthy, Kumaran, Liu, Joceline S., Miles, Brian J., Lipshultz, Larry I., Khera, Mohit·2013·Journal of Urology

DOI 10.1016/j.juro.2013.02.002PMC PMC4544840

Open this paper in CoChat — free account

Abstract

PURPOSE: Testosterone replacement therapy in men with prostate cancer is controversial, with concern that testosterone can stimulate cancer growth. We evaluated the safety and efficacy of testosterone in hypogonadal men with prostate cancer treated with radical prostatectomy. MATERIALS AND METHODS: We performed a review of 103 hypogonadal men with prostate cancer treated with testosterone after prostatectomy (treatment group) and 49 nonhypogonadal men with cancer treated with prostatectomy (reference group). There were 77 men with low/intermediate (nonhigh) risk cancer and 26 with high risk cancer included in the analysis. All men were treated with transdermal testosterone, and serum hormone, hemoglobin, hematocrit and prostate specific antigen were evaluated for more than 36 months. RESULTS: Median (IQR) patient age in the treatment group was 61.0 years (55.0-67.0), and initial laboratory results included testosterone 261.0 ng/dl (213.0-302.0), prostate specific antigen 0.004 ng/ml (0.002-0.007), hemoglobin 14.7 gm/dl (13.3-15.5) and hematocrit 45.2% (40.4-46.1). Median followup was 27.5 months, at which time a significant increase in testosterone was observed in the treatment group. A significant increase in prostate specific antigen was observed in the high risk and nonhigh risk treatment groups with no increase in the reference group. Overall 4 and 8 cases of cancer recurrence were observed in treatment and reference groups, respectively. CONCLUSIONS: Thus, testosterone therapy is effective and, while followed by an increase in prostate specific antigen, does not appear to increase cancer recurrence rates, even in men with high risk prostate cancer. However, given the retrospective nature of this and prior studies, testosterone therapy in men with history of prostate cancer should be performed with a vigorous surveillance protocol.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.juro.2013.02.002

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Studies on Prostatic Cancer: I. The Effect of Castration, of Estrogen and of Androgen Injection on Serum Phosphatases in Metastatic Carcinoma of the Prostate
Huggins, C., & Hodges, C. V. (2002) · The Journal of Urology · doi:10.1016/s0022-5347(05)64820-3 · Cited by 3,856
Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline.
Bhasin, S., Cunningham, G. R., Hayes, F. J., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., & Montori, V. M. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2847 · Cited by 965
Investigation, treatment and monitoring of late-onset hypogonadism in males
Wang, C., Nieschlag, E., Swerdloff, R., Behre, H. M., Hellstrom, W. J., Gooren, L. J., Kaufman, J. M., Legros, J.-J., Lunenfeld, B., Morales, A., et al. (2008) · European Journal of Endocrinology · doi:10.1530/eje-08-0601 · Cited by 867
Variation in the Definition of Biochemical Recurrence in Patients Treated for Localized Prostate Cancer: The American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel Report and Recommendations for a Standard in the Reporting of Surgical Outcomes
Cookson, M. S., Aus, G., Burnett, A. L. “., Canby‐Hagino, E., D'Amico, A. V., Dmochowski, R. R., Eton, D. T., Forman, J. D., Goldenberg, S. L., Hernández, J., et al. (2007) · The Journal of Urology · doi:10.1016/j.juro.2006.10.097 · Cited by 848
Adverse Events Associated With Testosterone Replacement in Middle-Aged and Older Men: A Meta-Analysis of Randomized, Placebo-Controlled Trials
Calof, O. M., Singh, A. B., Lee, M. L., Kenny, A. M., Urban, R. J., Tenover, J. L., & Bhasin, S. (2005) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/60.11.1451 · Cited by 728
Risks of testosterone-replacement therapy and recommendations for monitoring.
Rhoden, E. L., & Morgentaler, A. (2004) · New England Journal of Medicine · doi:10.1056/nejmra022251 · Cited by 705
Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941.
Huggins, C., & Hodges, C. (2002) · Journal of Urology · doi:10.1016/s0022-5347(02)80307-x · Cited by 637
Shifting the Paradigm of Testosterone and Prostate Cancer: The Saturation Model and the Limits of Androgen-Dependent Growth
Morgentaler, A., & Traish, A. M. (2008) · European Urology · doi:10.1016/j.eururo.2008.09.024 · Cited by 469
Investigation, Treatment, and Monitoring of Late‐Onset Hypogonadism in Males: ISA, ISSAM, EAU, EAA, and ASA Recommendations
Wang, C., Nieschlag, E., Swerdloff, R. S., Behre, H. M., Hellstrom, W. J. G., Gooren, L. J., Kaufman, J., Legros, J. J., Lunenfeld, B., Morales, Á., et al. (2008) · Journal of Andrology · doi:10.2164/jandrol.108.006486 · Cited by 443
Effect of Testosterone Replacement Therapy on Prostate Tissue in Men With Late-Onset Hypogonadism: A Randomized Controlled Trial
Marks, L. S., Mazer, N. A., Mostaghel, E., Hess, D. L., Dorey, F. J., Epstein, J. I., Veltri, R. W., Makarov, D. V., Partin, A. W., Bostwick, D. G., et al. (2006) · JAMA · doi:10.1001/jama.296.19.2351 · Cited by 400

Flagged first, then by citations

Show all 33 references

1 of the 33 references couldn’t be matched to a known paper.

Sorted by citations

Items 101–183 of 183

Testosterone Replacement Therapy in Hypogonadal Men with a Prostate Cancer Diagnosis: A British Society for Sexual Medicine Consensus Statement
Edison, M. A., Kirby, M. G., & Hackett, G. I. (2025) · The World Journal of Men s Health · doi:10.5534/wjmh.250086 · Cited by 5
Hypogonadism and urologic surgeries: a narrative review
Fendereski, K., Ghaed, M. A., Calvert, J. K., & Hotaling, J. M. (2022) · Translational Andrology and Urology · doi:10.21037/tau-22-308 · Cited by 5
The Evaluation and Management of Testosterone Deficiency: the New Frontier in Urology and Men’s Health
Conners, W. P., & Morgentaler, A. (2013) · Current Urology Reports · doi:10.1007/s11934-013-0370-5 · Cited by 5
Testosterone Replacement Therapy: Who to Evaluate, What to Use, How to Follow, and Who is at Risk?
Afiadata, A., & ELLSWORTH, P. I. (2014) · Hospital Practice · doi:10.3810/hp.2014.12.1160 · Cited by 5
Practice Patterns in the Diagnosis and Management of Hypogonadism: A Survey of Sexual Medicine Society of North America Members
Yafi, F. A., Haney, N. M., Anaissie, J. E., DeLay, K. J., Trost, L. W., Khera, M., & Hellstrom, W. J. G. (2017) · Urology · doi:10.1016/j.urology.2017.04.036 · Cited by 5
Self-citation
Testosterone Management in Aging Males: Surveying Clinical Practices of Urologists and Endocrinologists in Israel
Ishay, A., Tzemah, S., Nitzan, R., Jehassi, A., & Cohen, M. (2019) · Sexual Medicine · doi:10.1016/j.esxm.2019.06.011 · Cited by 5
Updated Review of Testosterone Replacement Therapy in the Setting of Prostate Cancer
Polchert, M., Voznesensky, I., Soubra, A., & Hellstrom, W. J. G. (2021) · Androgens Clinical Research and Therapeutics · doi:10.1089/andro.2020.0013 · Cited by 5
Testosterone Therapy in Adult Males with Hypogonadism
Boeri, L., Masterson, T., Antonio, L., Corona, G., Khera, M., Salonia, P. A., & Mulhall, J. P. (2025) · European Urology · doi:10.1016/j.eururo.2025.12.015 · Cited by 7
Self-citation
Testosterone Therapy and Prostate Cancer
Morales, Á., & Siemens, D. R. (2022) · Urologic Clinics of North America · doi:10.1016/j.ucl.2022.07.002 · Cited by 4
Testosterone Effects on the Prostate Gland: Review of Pathophysiology and considerations in Prostate Cancer
Wilczynski, C. (2015) · Journal of Family Medicine and Disease Prevention · doi:10.23937/2469-5793/1510004 · Cited by 4
Testosterone therapy: where do the latest guidelines agree and differ?
Pelzman, D. L., & Hwang, K. (2020) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000581 · Cited by 4
Testosterone, HIV, and cardiovascular disease risk
Grant, J. K., Loyd, Q., & Martinez, C. A. (2020) · Cardiovascular Endocrinology & Metabolism · doi:10.1097/xce.0000000000000236 · Cited by 4
Strategies for Testosterone Therapy in Men with Metastatic Prostate Cancer in Clinical Practice: Introducing Modified Bipolar Androgen Therapy
Morgentaler, A. (2020) · Androgens Clinical Research and Therapeutics · doi:10.1089/andro.2020.0009 · Cited by 4
Do we have enough evidences that make you safe to treat a man with hypogonadism one year after a radical prostatectomy for prostate cancer? | Opinion: YES
Torres, L. O. (2018) · International braz j urol · doi:10.1590/s1677-5538.ibju.2018.0003 · Cited by 4
Hypogonadism and its treatment among prostate cancer survivors
Choi, E. J., Xu, P. J., El‐Khatib, F. M., Huynh, L. M., & Yafi, F. A. (2020) · International Journal of Impotence Research · doi:10.1038/s41443-020-00387-3 · Cited by 4
The Role of Serum Testosterone in the Pathogenesis and Treatment of Prostate Cancer: A Review Based on the Clinical Evidence
Zhao, X., Sakamoto, S., Yamada, Y., Sato, K., Tamura, T., Shibata, H., Sazuka, T., Imamura, Y., & Ichikawa, T. (2025) · International Journal of Urology · doi:10.1111/iju.70125 · Cited by 3
Oncological safety of testosterone replacement therapy in men with localised prostate cancer: a systematic review of observational studies
Santucci, J., Stapleton, P., Perera, M., Ischia, J. J., Murphy, D. G., Bolton, D. M., Lawrentschuk, N., Frydenberg, M., & Sathianathen, N. J. (2025) · British Journal of Urology · doi:10.1111/bju.16870 · Cited by 3
Benefits and risks of testosterone therapy in older men.
Attard, C. D. C., & Fava, S. (2019) · Minerva urologica e nefrologica = The Italian journal of urology and nephrology · doi:10.23736/s0393-2249.19.03301-0 · Cited by 3
Measuring testosterone and testosterone replacement therapy in men receiving androgen deprivation therapy for prostate cancer: A survey of UK uro‐oncologists' opinions and practice
Payne, H. A., McMenemin, R. M., Bahl, A. K., Greene, D. R., & Staffurth, J. N. (2018) · International Journal of Clinical Practice · doi:10.1111/ijcp.13292 · Cited by 3
Prevalence of Hypogonadism in Low-Risk Prostate Cancer Survivors.
Agrawal, L., Arceo-Mendoza, R. M., Barnosky, A., Bresler, L., Chiha, M., Silva, A., & Wilczynski, C. (2016) · Europe PMC (PubMed Central) · Cited by 3
Testosterone and the Prostate
Tan, R., Silberstein, J. L., & Hellstrom, W. J. G. (2014) · Sexual Medicine Reviews · doi:10.1002/smrj.29 · Cited by 3
Pharmacologic and surgical therapies for sexual dysfunction in male cancer survivors.
Kadıoğlu, A., Ortaç, M., & Brock, G. B. (2015) · PubMed Central · doi:10.3978/j.issn.2223-4683.2014.12.03 · Cited by 3
Testosterone Deficiency, Supplementation, and Prostate Cancer: Maintaining a Balanced Perspective
Trost, L. W., & Hellstrom, W. J. G. (2013) · The Journal of Sexual Medicine · doi:10.1111/jsm.12370 · Cited by 3
Male Hypogonadism
Hohl, A., & Ronsoni, M. F. (2022) · Springer eBooks · doi:10.1007/978-3-030-90684-9_14 · Cited by 2
Testosterone Treatment of Men with Unequivocal Hypogonadism Following Treatment of Organ-Confined Prostate Cancer
Jones, R. B., & Snyder, P. J. (2023) · Endocrine Practice · doi:10.1016/j.eprac.2023.05.008 · Cited by 2
Testosterone Therapy: Injectable Androgens
Yassin, A. A. (2023) · Springer eBooks · doi:10.1007/978-3-031-31501-5_15 · Cited by 2
Testosterone Replacement Therapy in Men with Prostate Cancer after Proton Therapy
Bryant, C., Hoppe, B. S., Mendenhall, N. P., Henderson, R. H., Nichols, R. C., Morris, C. G., WILLIAMS, C. R., Harris, S. E., Su, Z., Li, Z., et al. (2014) · International Journal of Particle Therapy · doi:10.14338/ijpt-14-00004.1 · Cited by 2
Effect of serum testosterone and percent tumor volume on extra-prostatic extension and biochemical recurrence after laparoscopic radical prostatectomy
Kwon, D., Hwang, E. C., Yu, S., Jo, Y., Jung, S., Kang, T., Choi, C., Heo, S., Hwang, J., Jung, S., et al. (2015) · Asian Journal of Andrology · doi:10.4103/1008-682x.154317 · Cited by 2
Monitoring of Testosterone Replacement Therapy to Optimize the Benefit-to-Risk Ratio
Hayes, F. J. (2022) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2021.11.013 · Cited by 3
Evolution of the views on the role of testosterone in prostate cancer. Literature review
Ахвледиани, Н. Д., Babaev, M. U., & Solovyev, V. V. (2023) · Andrology and Genital Surgery · doi:10.17650/2070-9781-2022-23-4-26-35 · Cited by 2
The role of endogenous testosterone in relationship with low- and intermediate-risk prostate cancer: a systematic review
Porcaro, A. B., Serafin, E., Brusa, D., Costantino, S., Brancelli, C., Cerruto, M. A., & Antonelli, A. (2024) · Asian Journal of Andrology · doi:10.4103/aja202443 · Cited by 2
USE OF TESTOSTERONE REPLACEMENT THERAPY AFTER RADICAL PROSTATECTOMY MIGHT KILL TWO BIRDS WITH ONE STONE FROM THE PERSPECTIVE OF MEN’S HEALTH AND DISEASE CONTROL
Nam, J. K., Lee, K. S., & Kim, T. N. (2020) · Journal of Men s Health · doi:10.15586/jomh.v16isp1.271 · Cited by 2
Benefits and Risks of Testosterone Therapy in Men With Testosterone Deficiency
Traish, A. M., & Morgentaler, A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813197-8.00018-x · Cited by 2
Can Testosterone Therapy Be a Viable Option for Men Suffering With the Effects From Hypogonadism due to Prostate Cancer Treatment?
Kirby, M. G., Naranjo, A., Ellis, L., & Alaka, M. (2025) · Clinical Oncology · doi:10.1016/j.clon.2025.103778 · Cited by 1
Testosterone replacement therapy following definitive treatment for prostate cancer: a scoping review of safety and efficacy
Gibson, J., George, M., Grice, P., Mohee, A., Stasinou, T., Pearce, I., & Modgil, V. (2025) · International Journal of Impotence Research · doi:10.1038/s41443-025-01206-3 · Cited by 1
The interplay between testosterone and depression: bridging research, clinical applications, and health: a narrative review
Abadom, M., Nyong, E., Hernandez, B. S., Saffati, G., Parikh, N. N., & Khera, M. (2026) · Sexual Medicine Reviews · doi:10.1093/sxmrev/qeag024 · Cited by 1
Self-citation
Current State of Penile Rehabilitation After Robotic Prostatectomy
Wright, C., Sujka, J. A., & Shin, D. (2014) · Current Sexual Health Reports · doi:10.1007/s11930-014-0019-5 · Cited by 1
Andrology: Puberty-Fertility-Andropause
Guo, D. P., & Eisenberg, M. L. (2015) · Springer eBooks · doi:10.1007/978-1-4939-3237-5_9 · Cited by 2
Erectile Dysfunction in the Setting of Prostate Cancer
Samplaski, M. K., & Lo, K. C. (2016) · Springer eBooks · doi:10.1007/978-1-4939-3100-2_9 · Cited by 1
Safety of androgen therapy in men with prostate cancer
Rajan, P., Tharakan, T., & Chen, R. (2022) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2022.101628 · Cited by 1
Testosterone therapy in prostate cancer: is it still a controversy?
Bart, A. S., Hoof, A. V., Badre-Hume, R., Selvarajah, J., Robillard, K., & Albala, D. M. (2022) · Current Opinion in Urology · doi:10.1097/mou.0000000000001039 · Cited by 1
Chapter 29: Male sexual dysfunction in type 2 diabetes
SEMSDA Committee (2018) · South African Family Practice · doi:10.4102/safp.v60i4.4905 · Cited by 1
A relação da Terapia de Reposição de Testosterona (TRT) com o Câncer de Próstata: uma revisão integrativa
Cunha, R. R. D. O., Mendanha, V. C., Pereira, G. D. O., França, H. V. D., Júnior, E. P. D. S., Coelho, V. A. B., & Arruda, J. T. (2024) · STUDIES IN HEALTH SCIENCES · doi:10.54022/shsv5n2-004 · Cited by 1
Bipolar Androgen Therapy in Prostate Cancer (Update)
Lo, E. M., Balasubramanian, A., Pastuszak, A. W., & Khera, M. (2020) · The Journal of Sexual Medicine · doi:10.1016/j.jsxm.2019.12.022 · Cited by 1
Self-citation
PSA Testing in Men Receiving Testosterone Therapy With History of Prostate Cancer: A Matched Analysis of a Large Multi-Institutional Research Network
Mason, M. M., Nackeeran, S., Lokeshwar, S. D., Blachman-Braun, R., & Ramasamy, R. (2022) · Urology · doi:10.1016/j.urology.2022.02.010 · Cited by 1
Testosterone Therapy in Advanced Prostate Cancer
Chedrawe, E. R., Sathe, A. A., White, J., Ory, J., & Ramasamy, R. (2022) · Androgens Clinical Research and Therapeutics · doi:10.1089/andro.2021.0035 · Cited by 1
Re: Incidence of Prostate Cancer in Hypogonadal Men Receiving Testosterone Therapy: Observations from 5-Year Median Followup of 3 Registries
Butler, P. R., Scovell, J. M., Ramasamy, R., & Lipshultz, L. I. (2015) · European Urology · doi:10.1016/j.eururo.2015.02.014 · Cited by 1
Self-citation
First, do no harm: The unclear benefit of lifelong castration for patients with metastatic prostate cancer
Sena, L. A., Wang, H., & Denmeade, S. R. (2023) · The Prostate · doi:10.1002/pros.24582 · Cited by 1
Re: Preoperative Erectile Function is the Only Predictor of the Use of a High Number of Phosphodiesterase Type-5 Inhibitors after Bilateral Nerve-Sparing Radical Prostatectomy
Seftel, A. D. (2014) · The Journal of Urology · doi:10.1016/j.juro.2014.08.073
Malignant medication? Testosterone and cancer
Pastuszak, A. W. (2015) · British Journal of Urology · doi:10.1111/bju.12822
Self-citation
Addressing the pressing issues related to testosterone administration to men with prostate cancer
Morales, Á. (2016) · Canadian Urological Association Journal · doi:10.5489/cuaj.3824
Testosterone Therapy in Hypogonadal Men with Prostate Cancer
Kaplan, J. R. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800077-9.00067-0
Testosterone Therapy: Injectable Androgens
Yassin, A. A. (2017) · Springer eBooks · doi:10.1007/978-3-319-46086-4_12
Do we have enough evidences that make you safe to treat a man with hypogonadism one year after a radical prostatectomy for prostate cancer? | Opinion: Not Yet
Wroclawski, M. L., & Heldwein, F. L. (2018) · International braz j urol · doi:10.1590/s1677-5538.ibju.2018.0004
Overview of Toxicity Outcomes with Prostate SBRT and Comparison to Other Treatment Interventions (Urinary, Rectal and Sexual Outcomes)
Repka, M., Suy, S., Kataria, S. K., Kole, T. P., Paydar, I., Collins, B. T., Lischalk, J. W., Obayomi-Davies, O., & Collins, S. P. (2018) · Springer eBooks · doi:10.1007/978-3-319-92453-3_8
Hormone replacement therapy in patients with a history of cancer
Левченко, Н. Е., Efremov, E. A., Владимировна, К. Е., Sidorenko, Y. S., Melnik, Y. I., & Koryakin, A. V. (2019) · Practical oncology · doi:10.31917/2004310
PICO: Testosteronsuppletie bij prostaatcarcinoom na curatieve behandeling of onder active surveillance
Kolenburg, J., & de Vries, P. (2020) · Tijdschrift voor Urologie · doi:10.1007/s13629-020-00292-w
Editorial Comment: Testosterone replacement therapy (TRT) and prostate cancer: An updated systematic review with a focus on previous or active localized prostate cancer
Javaroni, V. (2022) · International braz j urol · doi:10.1590/s1677-5538.ibju.2022.01.08
Faculty Opinions recommendation of Can testosterone therapy be offered to men on active surveillance for prostate cancer? Preliminary results.
Minhas, S., Tharakan, T., & Miah, S. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.727802981.793556568
Testosterone Therapy and Prostate Cancer
Soares, D. D. F. G., Rhoden, E. L., & Morgentaler, A. (2017) · Springer eBooks · doi:10.1007/978-3-319-46086-4_15
This Month in Adult Urology
Steers, W. D. (2013) · The Journal of Urology · doi:10.1016/j.juro.2013.04.081
Faculty Opinions recommendation of Shifting the paradigm of testosterone replacement therapy in prostate cancer.
Minhas, S., Miah, S., & Tharakan, T. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.735112639.793556659
The Role of Post-Radical Prostatectomy Testosterone Therapy in Erectile Function Recovery
Huynh, L. M., Gevorkyan, R., & Ahlering, T. E. (2022) · Androgens Clinical Research and Therapeutics · doi:10.1089/andro.2022.0005
Testosterone Therapy in Men on Active Surveillance
Chun, T., Tannenbaum, J., Watts, H., Voznesensky, I., Almajed, W., & Hellstrom, W. J. G. (2022) · Androgens Clinical Research and Therapeutics · doi:10.1089/andro.2022.0004
An Approach to Testosterone Therapy in Men After Treatment for Localized Prostate Cancer
Reeves, A., Barham, D. W., & Yafi, F. A. (2022) · Androgens Clinical Research and Therapeutics · doi:10.1089/andro.2021.0031
Blood-based LC-MS/MS analysis of steroids in prostate and ovarian cancer diagnostics
van Winden, L. J. (2023) · doi:10.33540/1680 · Cited by 1
Testosterone Therapy and Prostate Cancer
Rhoden, E. L., Soares, D. D. F. G., & Morgentaler, A. (2023) · Springer eBooks · doi:10.1007/978-3-031-31501-5_18
Sexual Dysfunction
Schover, L. R. (2017) · Holland‐Frei Cancer Medicine · doi:10.1002/9781119000822.hfcm138
Research Progress on the Relationship between Serum Testosterone and Prostate Cancer
卓, 涛. (2023) · Advances in Clinical Medicine · doi:10.12677/acm.2023.13122836
Seksualiteit en androgeendeprivatietherapie bij de behandeling van prostaatkanker – een narratieve review
Nicolai, M. P. J. (2024) · Tijdschrift voor Urologie · doi:10.1007/s13629-024-00421-9
Evaluating the impact of pre‐diagnostic use of statins and testosterone replacement therapy on mortality outcomes in older men with hormone‐related cancers: Surveillance, Epidemiology, and End Results‐Medicare 2007–2015
Hussain, M. R., Abdelgadir, O., Polychronopoulou, E., Tsilidis, K. K., Alzweri, L. M., Tezanos, A. G. V., Baillargeon, J., Canfield, S. E., Kuo, Y., & López, D. S. (2024) · Andrology · doi:10.1111/andr.13616
Testosterontherapie: injizierbare Androgene
Yassin, A. A. (2024) · Springer eBooks · doi:10.1007/978-3-031-65245-5_15
Testosterontherapie und Prostatakrebs
Rhoden, E. L., Soares, D. D. F. G., & Morgentaler, A. (2024) · Springer eBooks · doi:10.1007/978-3-031-65245-5_18
Response to Comment: Testosterone deficiency in men with end-stage renal disease and kidney transplantation: a narrative review
Rinehart, C., Waggener, K., Deebel, N. A., & Terlecki, R. P. (2025) · International Journal of Impotence Research · doi:10.1038/s41443-025-01097-4
Testosterone Therapy and the Prostate
Morgentaler, A. (2025) · Springer eBooks · doi:10.1007/978-3-031-89650-7_21
Practical Perspectives in Testosterone Therapy
Salter, C. A., Mulhall, J. P., & Schlegel, P. N. (2025) · Springer eBooks · doi:10.1007/978-3-031-55405-6_50
Testosterone and Prostate Cancer
Khera, M., Saffati, G., & Rendon, D. O. (2025) · Springer eBooks · doi:10.1007/978-3-031-96376-6_32
Self-citation
Clinical Oncological Tolerance of Testosterone Replacement Therapy Over Two Years Among Patients With High-Risk or Very High-Risk Prostate Cancer Undergoing Radiotherapy
Shigehara, K., Naito, R., Kawahara, T., Kato, Y., Shinzawa, R., Yaegshi, H., Nohara, T., Izumi, K., & Mizokami, A. (2025) · Cureus · doi:10.7759/cureus.92806
Etiology of testosterone deficiency after radical prostatectomy
Hammad, M. A. M., Bandaru, D., Furlan, V. A., Hwang, Y., Yafi, F. A., Daneshvar, M., Lee, D., Ahlering, T. E., & Shahait, M. (2026) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2026.111035
Oncological Safety of Testosterone Replacement Therapy in Men With a History of Prostate Cancer: A Systematic Review
Alves, V. A. A., Silva, A. A. B., Bisneto, E. L. F., Macedo, H. F., Lima, G. S., Souza, L. G. P. S. D., Barbosa, P. E. A., & Júnior, P. F. D. M. (2026) · Cureus · doi:10.7759/cureus.104765
The Evidence-Practice Gap in Testosterone Therapy for Prostate Cancer: A Narrative Review
Aly, M., Joseph, A. A., & Amer, T. (2026) · Cureus · doi:10.7759/cureus.110973
Testosterone Therapy After Radical Prostatectomy: Insights From a Systematic Review and Meta‐Analysis
Corona, G., Morgado, A., Capogrosso, P., Boeri, L., Bettocchi, C., Rastrelli, G., Vignozzi, L., Maggi, M., Minhas, S., & Salonia, A. (2026) · Andrology · doi:10.1111/andr.70285
Re: Etiology of testosterone deficiency after radical prostatectomy
Croll, B. J. (2026) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2026.04.013

Authors: Pastuszak, A. W., Pearlman, A. M., Lai, W. S., Godoy, G., Sathyamoorthy, K., Liu, J. S., Miles, B. J., Lipshultz, L. I., & Khera, M.
Affiliations: Baylor College of Medicine (US)
University of Pennsylvania (US)
Northwestern University (US)
Houston Methodist (US)
ORCID: Pastuszak, Alexander W.
Pearlman, Amy M.
Godoy, Guilherme
Miles, Brian J.
Lipshultz, Larry I.
Khera, Mohit
Venue: Journal of Urology
Publisher: Ovid Technologies (Wolters Kluwer Health)
Published: 2013-08
Volume: 190
Issue: 2
Pages: 639-644
ISSN: 0022-5347 (ISSN-L)
1527-3792
DOI: 10.1016/j.juro.2013.02.002
PMC: PMC4544840
OpenAlex: W2091445581
Cited by: 183
References: 33
Citations by year: 2026: 6 · 2025: 12 · 2024: 9 · 2023: 9 · 2022: 18 · 2021: 6 · 2020: 15 · 2019: 15 · 2018: 11 · 2017: 10 · 2016: 13 · 2015: 27 · 2014: 26 · 2013: 6
FWCI: 18.92
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: The Journal of Urology (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: National Cancer Institute (K23CA160664)
Topics: Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
Health Sciences › Medicine › Urology › Prostate Cancer Diagnosis and Treatment
Keywords: testosterone replacement therapy, prostate cancer, radical prostatectomy, hypogonadism, transdermal testosterone, prostate-specific antigen, tumor recurrence, high-risk prostate cancer, low-risk prostate cancer, hemoglobin, hematocrit, hormone therapy safety
MeSH terms: Aged, Hematocrit, Hemoglobins, Humans, Hypogonadism, Male, Middle Aged, Prostatectomy, Prostatic Neoplasms, Retrospective Studies, Testosterone, Linear Models, Treatment Outcome, Prostate-Specific Antigen, Statistics, Nonparametric, Hormone Replacement Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Testosterone Replacement Therapy in Patients with Prostate Cancer After Radical Prostatectomy

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks